FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology and molecular biology, to genetic engineering. Described is a codon-optimised nucleic acid with a nucleotide sequence Seq Id No.: 2, encoding human aipl1. Presented is an expression vector containing said nucleic acid.
EFFECT: possibility of increasing the level of hAIPL1 mRNA by at least 15%, and the level of heterologous protein product by at least 29%; invention can be used for gene replacement therapy of type 4 Leber amaurosis.
9 cl, 10 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID CONSTRUCTIONS AND VECTORS FOR GENOTHERAPY FOR TREATING WILSON'S DISEASE AND OTHER CONDITIONS | 2015 |
|
RU2745567C2 |
| CHIMERIC PROTEINS BASED ON HUMAN UTROPHIN AND DYSTROPHIN AND USE THEREOF FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | 2021 |
|
RU2767335C1 |
| METHOD OF CONTROL OF HEART RHYTHM AND REDUCTION OF INDIVIDUAL CARDIOMYOCYTES USING THERMOGENETICS | 2022 |
|
RU2802995C1 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| NUCLEOTIDE SEQUENCE ENCODING β-N-ACETYLHEXOZAAMINIDASE AGGREGATIBACTER ACTINOMYCETEMCOMITANS AND GENETIC STRUCTURES CONTAINING IT | 2021 |
|
RU2789544C1 |
| METHOD FOR PRODUCING CHEMICAL PRODUCTS OF SUBTLE SYNTHESIS USING CORYNEBACTERIUM SECRETING MODIFIED a-1,6-GLUCOSIDASES | 2018 |
|
RU2763317C2 |
| HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
| ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
